Day: November 17, 2019
All amounts expressed in U.S. dollarsTORONTO, Nov. 17, 2019 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) today announced it has reached an agreement to sell its 50 percent interest in Kalgoorlie Consolidated Gold Mines (“KCGM”) in Western Australia to Saracen Mineral Holdings Limited (“Saracen”) for a total consideration of $750 million in cash.“The sale of our non-operating interest in KCGM represents the first step in our plan to realize in excess of $1.5 billion from the disposal of non-core assets by the end of next year. While this iconic gold mine has been a valuable contributor to Barrick over the years, the asset does not fit with our strategy of operating mines that we own. The sale allows us to further focus our portfolio on core operations,” says Mark Bristow, Barrick president...
Skeljungur hf.: Chief Financial Officer resigns
Written by Customer Service on . Posted in Public Companies.
Benedikt Ólafsson, Chief Financial Officer, has resigned. Benedikt Ólafsson has worked for the company for almost 4 years. Benedikt sat on the Board of Directors of Skeljungur year 2013 – 2016 before he became the Chief Financial Officer of the company.Benedikt Ólafsson:“I would like to thank the board of directors and employees of the company for the time I have worked for Skeljungur, both as a board member and later as an employee. It was both enjoyable and a great learning experience to take part in the listing of Skeljungur and the company’s development after that. I think this is the right time for me to make changes and I wish Skeljungur’s employees all the best in the years to come.”Árni Pétur Jónsson, CEO of Skeljungur:“I would like to thank Benedikt for the good work he has done for Skeljungur through the years. Benedikt has...
Skeljungur hf.: Framkvæmdastjóri fjármálasviðs segir upp störfum
Written by Customer Service on . Posted in Public Companies.
Benedikt Ólafsson, framkvæmdastjóri fjármálasviðs Skeljungs hf., hefur sagt starfi sínu lausu. Benedikt hefur unnið fyrir félagið í nærri 4 ár. Hann sat í stjórn Skeljungs frá árinu 2013 til 2016 áður en hann tók við sem framkvæmdastjóri fjármálasviðs.Benedikt Ólafsson:„Ég vil þakka stjórn og starfsmönnum félagsins kærlega fyrir þann tíma sem ég hef haft aðkomu að félaginu, bæði sem stjórnarmaður og síðar starfsmaður. Það var lærdómsríkt og skemmtilegt að fá að taka þátt í skráningu félagsins á markað og framgangi þess í framhaldinu. Ég tel þetta vera réttan tímapunkt fyrir mig til að gera breytingar og óska ég starfsmönnum félagsins alls hins besta á komandi árum.“Árni Pétur Jónsson, forstjóri Skeljungs:„Ég vil þakka Benedikt fyrir það góða starf sem hann hefur unnið fyrir Skeljung. Benedikt hefur gengt lykilhlutverki hjá fyrirtækinu...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
Written by Customer Service on . Posted in Public Companies.
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia. Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) added onto maximally tolerated statin therapy. Bempedoic acid and the bempedoic acid 180 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets’ new drug applications (NDAs) are currently under regulatory review by the U.S. Food and Drug Administration (FDA) and the marketing authorisation applications (MAAs) are currently under centralized review by the European Medicines Agency (EMA).The presentation, titled “Bempedoic...
HP Board of Directors Unanimously Rejects Unsolicited Xerox Proposal
Written by Customer Service on . Posted in Public Companies.
PALO ALTO, Calif., Nov. 17, 2019 (GLOBE NEWSWIRE) — HP Inc. (NYSE: HPQ) today announced that its Board of Directors has unanimously rejected the unsolicited proposal from Xerox Holdings Corporation to acquire the Company.Following is the full text of the letter that was sent on November 17, 2019 to John Visentin, Xerox Vice Chairman and CEO:Dear John,Our Board of Directors has reviewed and considered your unsolicited proposal dated November 5, 2019 at a meeting with our financial and legal advisors and has unanimously concluded that it significantly undervalues HP and is not in the best interests of HP shareholders. In reaching this determination, the Board also considered the highly conditional and uncertain nature of the proposal, including the potential impact of outsized debt levels on the combined company’s stock.We have great...
Orezone Results Support Presence of Higher-Grade Plunging System at the Bomboré Gold Project
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, Nov. 17, 2019 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSXV:ORE) (the “Company”) is pleased to report the successful results from its 2019 drill programme which was designed to test and validate the refined geological interpretation of a higher-grade plunging gold system within the existing lower-grade mineralization at its 90%-owned Bomboré Gold Project in Burkina Faso, West Africa.Highlights:BBD1034: 8.9 m of 3.21 g/t gold including 1 m of 16.25 g/t goldBBC4995: 8 m of 3.04 g/t gold including 3 m of 5.71 g/t goldBBC4996: 18 m of 3.68 g/t gold including 8 m of 7.31 g/t goldBBC4997: 4 m of 3.74 g/t gold including 1 m of 13.35 g/t goldBBC4999: 11 m of 1.89 g/t gold including 4 m of 4.53 g/t goldBBC5000: 12 m of 3.09 g/t gold including 6 m of 5.16 g/t goldOn September 11, 2019, Orezone announced a...
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Written by Customer Service on . Posted in Public Companies.
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men2 Among patients who had been previously hospitalized, those who were screened during or within 30 days of hospitalization showed the greatest treatment effect with Entresto, compared to valsartan3 Safety and tolerability of Entresto, where evaluated, were consistent with previously reported findings1,2,4,5 New analyses follow full results from the PARAGON-HF trial, which show overall treatment effect, despite narrow miss on statistical significance4The digital press release with multimedia content can be accessed here: Basel, November 17, 2019 —...